Drug Susceptibility of Mycobacterium tuberculosis Beijing Genotype and Association with MDR TB

Jurriaan E.M. de Steenwinkel, Marian T. ten Kate, Gerjo J. de Knegt, Kristin Kremer, Rob E. Aarnoutse, Martin J. Boeree, Henri A. Verbrugh, Dick van Soolingen, and Irma A.J.M. Bakker-Woudenberg

To determine differences in the ability of Mycobacterium tuberculosis strains to withstand antituberculosis drug treatment, we compared the activity of antituberculosis drugs against susceptible Beijing and East-African/Indian genotype M. tuberculosis strains. Beijing genotype strains showed high rates of mutation within a wide range of drug concentrations, possibly explaining this genotype's association with multidrug-resistant tuberculosis.

The emergence of Mycobacterium tuberculosis resistance to antituberculosis (anti-TB) drugs is a major public health challenge that is threatening World Health Organization targets set for the elimination of TB (1). Approximately 500,000 cases of multidrug-resistant TB (MDR TB) are diagnosed annually, but the true magnitude of the MDR TB problem is not known because adequate laboratory tools are lacking. Multiple factors contribute to low cure rates, treatment failures, and relapses: poor-quality guidance regarding treatment, HIV co-infection, transmission of resistant forms of TB, and relapses; poor-quality guidance regarding treatment, HIV co-infection, transmission of resistant forms of TB, and relapses; poor-quality guidance regarding treatment, HIV co-infection, transmission of resistant forms of TB, and relapses. The modern lineage, and the EAI genotype is believed to represent an evolutionary lineage more closely related to the common ancestor of the M. tuberculosis complex.

We compared the in vitro activity of anti-TB drugs against susceptible Beijing and EAI M. tuberculosis isolates from Vietnam and determined the in vitro mutation frequency of these strains during drug exposure. We also determined time-kill kinetics of anti-TB drugs and assessed the emergence of resistant mutants and the concentration range within which resistant mutants and no susceptible mycobacteria were selected. The concentration at which resistant mutants did not emerge (the mutant prevention concentration) was also ascertained. By using this approach, we established an in vitro model for determining differences in the ability of M. tuberculosis strains to resist anti-TB drug treatment.

The Study

Results of a liquid culturing system (BD BACTEC MGIT 960 System; BD Diagnostics, Sparks, MD, US) (for details, see the online Technical Appendix, wwwnc.cdc.gov/EID/pdfs/11-0912-Techapp.pdf) showed that all 5 Beijing and 5 EAI genotype strains were susceptible to isoniazid (INH), rifampin (RIF), moxifloxacin (MXF), and amikacin (AMK). MICs were determined by using the agar proportion method (11), which showed that ranges were small for the Beijing and EAI genotype strains: INH, 0.062–0.125 mg/L; RIF, 0.125–1 mg/L; MXF, 0.125–0.5 mg/L; and AMK, 0.5–2 mg/L. Duplicate values showed only minor differences.

We determined the mutation frequencies of the Beijing and EAI genotype strains by using previously defined critical drug concentrations of 1 mg/L for INH, RIF, and
Low concentrations of RIF were needed to achieve >99% activity toward low-density cultures of the 2 strains (Beijing-1585 and EAI-1627 were investigated as described in Figure 1). The differences in the mutation frequencies of Beijing and EAI genotype strains were similar for INH, MXF, and AMK, but they were significantly different for RIF (1.6 × 10⁻⁶ to 5.4 × 10⁻³ for Beijing strains vs. 6.3 × 10⁻⁷ to 3.8 × 10⁻⁴ for EAI strains; p = 0.003, unpaired Mann-Whitney test) (Table 1; Figure 1). Because rifamycin drugs are widely used to treat TB, the difference in the mutation frequencies of Beijing and EAI genotype strains for RIF is a major finding.

For Beijing genotype strains, the increase in mutation frequency during exposure to RIF could be due to described missense mutations in the mut genes (13). Such mutations in the mut genes can change the DNA repair mechanism; as a consequence, the frequency of resistant mutant formation might increase. However, a direct correlation between the occurrence of particular mutations in mut genes and altered mutation frequency has not been proven. Furthermore, Werngren and Hoffner (14) found an equal mutation frequency for Beijing (3.6 × 10⁻⁴) and non-Beijing (4.4 × 10⁻⁴) genotypes. A possible explanation for the discrepancy in findings might be the concentration of RIF used in the subculture plates. In our study, the critical concentration of 1 mg/L RIF was used (11), whereas Werngren and Hoffner used a concentration of 2 mg/L RIF. In addition, Werngren and Hoffner compared the Beijing and non-Beijing genotypes of several genotype families, whereas we compared Beijing and EAI genotype strains that were selected from the same tuberculosis-endemic area and during the same period.

We determined the time-kill kinetics of RIF toward 2 strains with significantly different mutation frequencies: Beijing-1585 (3.7 × 10⁻³ [3.0 × 10⁻³ and 4.3 × 10⁻³, duplicates]) and EAI-1627 (3.5 × 10⁻⁶ [2.8 × 10⁻⁶ and 4.1 × 10⁻⁶, duplicates]). Cultures with low and high densities of Beijing-1585 and EAI-1627 were investigated as described (15). RIF showed strong time- and concentration-dependent activity toward low-density cultures of the 2 strains (Figure 2). Low concentrations of RIF were needed to achieve >99% mycobacterial killing; differences between Beijing-1585 and EAI-1627 were minor (Table 2). However, to achieve 100% killing, especially for Beijing-1585, RIF concentrations had to be increased substantially (Table 2). Compared with the low-density culture for Beijing-1585, a substantial increase in RIF concentrations was needed to achieve 100% killing of the high-density culture (Table 2). This finding may be relevant in the clinical context because high-density mycobacteria populations are expected to exist in infected tissues of TB patients.

RIF-resistant mutants did not emerge in low-density cultures of Beijing-1585 and EAI-1627. However, RIF-resistant mutants were selected at relatively high numbers from high-density Beijing-1585 cultures compared with high-density EAI-1627 cultures. In Beijing-1585 cultures,

![Figure 1. Frequency of rifampin (RIF)-resistant mutants in Mycobacterium tuberculosis Beijing and East-African/Indian (EAI) genotype strains (5 strains each) originating from Vietnam. Mutation frequencies were determined in duplicate. Statistical analysis was performed by using an unpaired Mann-Whitney test.](image)

### Table 1. Mutation frequency of *Mycobacterium tuberculosis* genotype strains originating from Vietnam, by antituberculosis drug

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Isoniazid</th>
<th>Rifampin</th>
<th>Moxifloxacin</th>
<th>Amikacin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beijing 1585</td>
<td>5.7 × 10⁻⁶, 6.2 × 10⁻⁶</td>
<td>3.0 × 10⁻⁴, 4.3 × 10⁻³</td>
<td>4.3 × 10⁻⁸, 6.1 × 10⁻⁸</td>
<td>2.3 × 10⁻⁸, 3.2 × 10⁻⁸</td>
</tr>
<tr>
<td>Beijing 1607</td>
<td>8.6 × 10⁻⁶, 1.4 × 10⁻⁵</td>
<td>1.5 × 10⁻³, 5.4 × 10⁻³</td>
<td>6.9 × 10⁻⁸, 2.4 × 10⁻⁷</td>
<td>8.6 × 10⁻⁸, 3.0 × 10⁻⁷</td>
</tr>
<tr>
<td>Beijing 2115</td>
<td>7.3 × 10⁻⁶, 1.1 × 10⁻⁵</td>
<td>1.0 × 10⁻², 9.2 × 10⁻²</td>
<td>1.0 × 10⁻⁸, 4.3 × 10⁻⁸</td>
<td>1.4 × 10⁻⁸, 2.8 × 10⁻⁸</td>
</tr>
<tr>
<td>Beijing 2121</td>
<td>6.8 × 10⁻⁶, 2.9 × 10⁻⁴</td>
<td>2.9 × 10⁻³, 1.9 × 10⁻³</td>
<td>1.1 × 10⁻⁸, 1.6 × 10⁻⁷</td>
<td>9.3 × 10⁻⁸, 1.1 × 10⁻⁷</td>
</tr>
<tr>
<td>Beijing 2145</td>
<td>9.1 × 10⁻⁶, 5.0 × 10⁻⁴</td>
<td>1.6 × 10⁻³, 5.5 × 10⁻³</td>
<td>7.9 × 10⁻⁸, 1.0 × 10⁻⁷</td>
<td>7.6 × 10⁻⁸, 1.1 × 10⁻⁷</td>
</tr>
<tr>
<td>East-African/Indian 1627</td>
<td>3.7 × 10⁻⁶, 6.5 × 10⁻⁶</td>
<td>4.1 × 10⁻⁴, 2.8 × 10⁻⁴</td>
<td>9.3 × 10⁻⁸, 1.5 × 10⁻⁷</td>
<td>5.6 × 10⁻⁸, 4.5 × 10⁻⁸</td>
</tr>
<tr>
<td>East-African/Indian 1606</td>
<td>8.7 × 10⁻⁶, 1.6 × 10⁻⁶</td>
<td>3.8 × 10⁻³, 2.7 × 10⁻³</td>
<td>3.2 × 10⁻⁸, 1.0 × 10⁻⁷</td>
<td>7.5 × 10⁻⁸, 1.5 × 10⁻⁷</td>
</tr>
<tr>
<td>East-African/Indian 1592</td>
<td>1.8 × 10⁻⁶, 2.6 × 10⁻⁶</td>
<td>3.0 × 10⁻³, 2.4 × 10⁻³</td>
<td>9.9 × 10⁻⁸, 4.5 × 10⁻⁸</td>
<td>9.4 × 10⁻⁸, 1.5 × 10⁻⁷</td>
</tr>
<tr>
<td>East-African/Indian 1596</td>
<td>3.9 × 10⁻⁶, 2.8 × 10⁻⁴</td>
<td>1.4 × 10⁻⁶, 3.9 × 10⁻⁶</td>
<td>1.7 × 10⁻⁷, 2.0 × 10⁻⁷</td>
<td>3.7 × 10⁻⁸, 3.2 × 10⁻⁷</td>
</tr>
<tr>
<td>East-African/Indian 2113</td>
<td>1.3 × 10⁻⁶, 4.1 × 10⁻⁶</td>
<td>6.7 × 10⁻⁸, 6.3 × 10⁻⁸</td>
<td>1.5 × 10⁻⁶, 1.0 × 10⁻⁷</td>
<td>4.4 × 10⁻⁸, 3.3 × 10⁻⁷</td>
</tr>
</tbody>
</table>

* Determined in duplicate.
exposure to RIF concentrations of 2–32 mg/L selected resistant mutants only; this was not observed in EAI-1627 cultures. Analysis of RIF-resistant Beijing mutants showed the following altered rpoB gene sequences: CAC→GAC (H526D), CAC→TAC (H526Y), and TCG→TTG (S531L), as assessed by using the GenoType MTBDRplus (Hain Lifescience, Nehren, Germany) assay (for details, see the online Technical Appendix).

For 3 of the 4 anti-TB drugs, the difference in the range of mutant prevention concentrations for the Beijing and EAI genotype strains was small: INH, 128–256 mg/L; RIF, 256–1,024 mg/L; and MXF, 2–8 mg/L. The mutant prevention concentration for AMK was >1,024 mg/L for all strains tested.

**Conclusions**

We showed that the currently used anti-TB drug susceptibility assays do not discriminate between the in vitro susceptibility, as determined by the methods used in this study, of the *M. tuberculosis* Beijing and EAI genotype strains. We also showed that the determination of mutation frequencies might be more informative than results of anti-TB drug susceptibility assays. For RIF, mutation frequencies in Beijing genotype strains were high compared with those in EAI genotype strains, and the selection of RIF-resistant mutants among Beijing strains, but not EAI strains, occurred within a wide range of RIF concentrations.

In addition, the killing capacity of RIF toward the Beijing genotype is dependent on the density of mycobacteria: high concentrations of RIF are required to achieve 100% killing of high-density Beijing genotype populations but not of high-density EAI genotype populations. These in vitro characteristics might contribute to the less favorable treatment outcome of Beijing genotype TB infections and their significant association with drug resistance. Our findings demonstrate the need for anti-TB drug treatments that will prevent resistance among *M. tuberculosis* Beijing genotype TB cases, and they suggest that the development of genotype-specific TB therapy might be justified.

---

**Table 2. Concentration- and time-dependent bactericidal effect of rifampin toward *Mycobacterium tuberculosis* genotypes in low- and high-density cultures**

<table>
<thead>
<tr>
<th>Day</th>
<th>Lowest RIF concentration resulting in killing of <em>M. tuberculosis</em>, mg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Beijing-1585 genotype</td>
</tr>
<tr>
<td></td>
<td>≥99% killing</td>
</tr>
<tr>
<td>1</td>
<td>Low†</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>0.001</td>
</tr>
</tbody>
</table>

*Cultures were exposed to RIF at 2-fold increasing concentrations for 6 days at 37°C; at indicated time-points, subcultures were performed on solid media for counting. Low, low-density culture; high, high-density culture; ND, not determined.
†Density of 5.1 × 10^5 CFU/mL.
‡Density of 4.4 × 10^6 CFU/mL.
§Density of 6.8 × 10^5 CFU/mL.
¶Density of 3.0 × 10^6 CFU/mL.*
Acknowledgments

We acknowledge RIVM for technical assistance and the National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, and the Pham Ngoc Thach Tuberculosis and Lung Disease Hospital, Ho Chi Minh City, Vietnam, for sharing their *M. tuberculosis* isolates.

Financial support was provided by Erasmus University Medical Center and RIVM.

Dr de Steenwinkel is a medical doctor, resident in training for medical microbiologist, and a PhD student in clinical microbiology and antimicrobial therapy at Erasmus University Medical Center. His interests include research on improving therapy for TB and fundamental exploration of resistance formation.

References


Address for correspondence: Jurriaan E.M. de Steenwinkel, Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; email: j.destenwinkel@erasmusmc.nl

Like our podcasts?
Sign up to receive email announcements when a new podcast is available.

www.cdc.gov/ncidod/eid/subcrib.htm